FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130831566> ?p ?o ?g. }

• W2130831566 endingPage "370S" @default.
• W2130831566 startingPage "364S" @default.
• W2130831566 abstract "Fondaparinux is the first of a new class of antithrombotic compounds, the synthetic pentasaccharides. By binding rapidly and strongly to antithrombin, its sole physiologic target in plasma, fondaparinux catalyzes specifically the inhibition of factor Xa, which results in effective and linear dose-dependent inhibition of thrombin generation. Fondaparinux does not bind to platelets. Its antithrombotic effect has been demonstrated in several animal models of arterial and venous thrombosis. At equivalent antithrombotic concentrations, fondaparinux induced less bleeding than unfractionated heparin in experimental bleeding models. Furthermore, it did not cross-react with sera from patients with heparin-induced thrombocytopenia. Administered subcutaneously, the absorption of fondaparinux is complete, rapid, and independent of dose. It has a linear pharmacokinetic profile, and its half-life of approximately 17 h allows for once-daily dosing. Fondaparinux is almost completely excreted by the kidneys. Owing to the limited intrasubject and intersubject variability, routine monitoring and dose adjustments should not be required for most patients. Fondaparinux has been approved for use in thromboprophylaxis after major orthopedic surgery, where it has demonstrated its efficacy compared to a low-molecular-weight heparin. Its clinical development in other indications is ongoing. Fondaparinux is the first of a new class of antithrombotic compounds, the synthetic pentasaccharides. By binding rapidly and strongly to antithrombin, its sole physiologic target in plasma, fondaparinux catalyzes specifically the inhibition of factor Xa, which results in effective and linear dose-dependent inhibition of thrombin generation. Fondaparinux does not bind to platelets. Its antithrombotic effect has been demonstrated in several animal models of arterial and venous thrombosis. At equivalent antithrombotic concentrations, fondaparinux induced less bleeding than unfractionated heparin in experimental bleeding models. Furthermore, it did not cross-react with sera from patients with heparin-induced thrombocytopenia. Administered subcutaneously, the absorption of fondaparinux is complete, rapid, and independent of dose. It has a linear pharmacokinetic profile, and its half-life of approximately 17 h allows for once-daily dosing. Fondaparinux is almost completely excreted by the kidneys. Owing to the limited intrasubject and intersubject variability, routine monitoring and dose adjustments should not be required for most patients. Fondaparinux has been approved for use in thromboprophylaxis after major orthopedic surgery, where it has demonstrated its efficacy compared to a low-molecular-weight heparin. Its clinical development in other indications is ongoing." @default.
• W2130831566 created "2016-06-24" @default.
• W2130831566 creator A5088333216 @default.
• W2130831566 date "2003-12-01" @default.
• W2130831566 modified "2023-09-27" @default.
• W2130831566 title "New Pentasaccharides for Prophylaxis of Deep Vein Thrombosis" @default.
• W2130831566 cites W114021389 @default.
• W2130831566 cites W1514571277 @default.
• W2130831566 cites W1536230526 @default.
• W2130831566 cites W1557422402 @default.
• W2130831566 cites W1628030746 @default.
• W2130831566 cites W1833703938 @default.
• W2130831566 cites W1891400877 @default.
• W2130831566 cites W1980998991 @default.
• W2130831566 cites W1983562338 @default.
• W2130831566 cites W1985407614 @default.
• W2130831566 cites W2000130043 @default.
• W2130831566 cites W2001790577 @default.
• W2130831566 cites W2010599049 @default.
• W2130831566 cites W2013537866 @default.
• W2130831566 cites W2024334081 @default.
• W2130831566 cites W2024483474 @default.
• W2130831566 cites W2041812149 @default.
• W2130831566 cites W2042096176 @default.
• W2130831566 cites W2048856171 @default.
• W2130831566 cites W2053677326 @default.
• W2130831566 cites W2054169479 @default.
• W2130831566 cites W2084679874 @default.
• W2130831566 cites W2087368566 @default.
• W2130831566 cites W2094069897 @default.
• W2130831566 cites W2107151252 @default.
• W2130831566 cites W2108471572 @default.
• W2130831566 cites W2133048039 @default.
• W2130831566 cites W2133155409 @default.
• W2130831566 cites W2149491841 @default.
• W2130831566 cites W2154872507 @default.
• W2130831566 cites W2166945512 @default.
• W2130831566 cites W2321004276 @default.
• W2130831566 cites W2325632732 @default.
• W2130831566 cites W2415882544 @default.
• W2130831566 cites W2416632942 @default.
• W2130831566 cites W2419459145 @default.
• W2130831566 cites W2434196378 @default.
• W2130831566 cites W2467760069 @default.
• W2130831566 cites W29582870 @default.
• W2130831566 cites W39606408 @default.
• W2130831566 cites W4245273215 @default.
• W2130831566 cites W4253259085 @default.
• W2130831566 doi "https://doi.org/10.1378/chest.124.6_suppl.364s" @default.
• W2130831566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14668419" @default.
• W2130831566 hasPublicationYear "2003" @default.
• W2130831566 type Work @default.
• W2130831566 sameAs 2130831566 @default.
• W2130831566 citedByCount "41" @default.
• W2130831566 countsByYear W21308315662012 @default.
• W2130831566 countsByYear W21308315662014 @default.
• W2130831566 countsByYear W21308315662015 @default.
• W2130831566 countsByYear W21308315662016 @default.
• W2130831566 countsByYear W21308315662017 @default.
• W2130831566 countsByYear W21308315662020 @default.
• W2130831566 countsByYear W21308315662021 @default.
• W2130831566 countsByYear W21308315662022 @default.
• W2130831566 crossrefType "journal-article" @default.
• W2130831566 hasAuthorship W2130831566A5088333216 @default.
• W2130831566 hasConcept C126322002 @default.
• W2130831566 hasConcept C2776877702 @default.
• W2130831566 hasConcept C2777015399 @default.
• W2130831566 hasConcept C2777292125 @default.
• W2130831566 hasConcept C2777557582 @default.
• W2130831566 hasConcept C2778205648 @default.
• W2130831566 hasConcept C2779026020 @default.
• W2130831566 hasConcept C2780868729 @default.
• W2130831566 hasConcept C2991741193 @default.
• W2130831566 hasConcept C42219234 @default.
• W2130831566 hasConcept C71924100 @default.
• W2130831566 hasConcept C89560881 @default.
• W2130831566 hasConcept C98274493 @default.
• W2130831566 hasConceptScore W2130831566C126322002 @default.
• W2130831566 hasConceptScore W2130831566C2776877702 @default.
• W2130831566 hasConceptScore W2130831566C2777015399 @default.
• W2130831566 hasConceptScore W2130831566C2777292125 @default.
• W2130831566 hasConceptScore W2130831566C2777557582 @default.
• W2130831566 hasConceptScore W2130831566C2778205648 @default.
• W2130831566 hasConceptScore W2130831566C2779026020 @default.
• W2130831566 hasConceptScore W2130831566C2780868729 @default.
• W2130831566 hasConceptScore W2130831566C2991741193 @default.
• W2130831566 hasConceptScore W2130831566C42219234 @default.
• W2130831566 hasConceptScore W2130831566C71924100 @default.
• W2130831566 hasConceptScore W2130831566C89560881 @default.
• W2130831566 hasConceptScore W2130831566C98274493 @default.
• W2130831566 hasIssue "6" @default.
• W2130831566 hasLocation W21308315661 @default.
• W2130831566 hasLocation W21308315662 @default.
• W2130831566 hasOpenAccess W2130831566 @default.
• W2130831566 hasPrimaryLocation W21308315661 @default.
• W2130831566 hasRelatedWork W1994434805 @default.
• W2130831566 hasRelatedWork W1994999842 @default.
• W2130831566 hasRelatedWork W2005793988 @default.

• next